Insights Into Potential Patient and Caregiver Benefits of Changing Disease Course in AD: A Discussion on the Non-Economic Values of Future Potential Early Intervention

Author(s)

Moderator: Samantha Benham-Hermetz, ., Alzheimer's Research UK, Cambridge, CAM, UK
Speakers: Frank Jessen, MD, PhD, Department of Psychiatry, University Hospital Cologne AöR, Bonn, Germany; Marc Wortmann, MD, PhD, Department of Psychiatry, University Hospital Cologne AöR, Zeist, UT, Netherlands; Samantha Benham-Hermetz, ., Alzheimer's Research UK, Cambridge, CAM, UK

The overall burden of Alzheimer’s disease (AD) is immense, and is known to be experienced more intensely as the disease progresses. With disease progression comes an increased need for support from others to complete everyday tasks and activities, and what some call “a loss of self”. But preceding these large steps in disease advancement are more subtle changes occurring earlier, and these subtle changes themselves can have a profound impact on early stage patients and their families. Future potential treatments for use in early AD that delay progression to later stages will be valued as they can allow for more time to be spent in earlier, less burdensome, segments of the disease.

This symposium provides a forum to discuss what this delay may mean from a humanistic perspective to patients and their caregivers, and how the value of future potential treatments for early AD should consider these critical non-economic elements. Specific considerations for what patients and caregivers or families of those in in early stages of disease value, as it often goes beyond the avoidance of medical resource utilization which is a common payer priority. The critical role and value of early diagnosis will also be discussed.

Conference/Value in Health Info

2020-11, ISPOR Europe 2020, Milan, Italy
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×